Cited by 87Cytokine Signaling Pathways and InteractionsNF-κB Signaling PathwaysTGF-β signaling in diseases

Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells

Open access
Huang, Wei-Lun, Yeh, Hsuan-Heng, Lin, Chien-Chung, Lai, Wu-Wei, Chang, Jang-Yang, Chang, Wen-Tsan, Su, Wu-Chou·2010·Molecular Cancer

Abstract

Background: Spontaneous interleukin-6 (IL-6) production has been observed in various tumors and implicated in the pathogenesis, progression and drug resistance in cancer. However, the regulation of IL-6 autocrine production in cancer cells is not fully understood. IL-6 is auto-regulated in many types of cell. Two of the three major downstream pathways of IL-6, MEK/extracellular signal-related kinase (Erk) pathway and phosphatidylinositol 3-kinase (PI3-K)/Akt pathway, have been shown to regulate IL-6 expression through the activation of AP-1 and NF-κB. However, it is not clear what the role of Janus kinase (Jak) 2/signal transducer and activator of transcription (Stat) 3 pathway. This study was designed to determine the role of Jak2/Stat3 pathway in the regulation of IL-6 autocrine production in cancer cells. Results: Inhibitors of Jak2/Stat3, MEK/Erk and PI3-K/Akt pathways down-regulated IL-6 secretion in the lung adenocarcinoma PC14PE6/AS2 (AS2) cells, which spontaneously secreted IL-6 and possessed constitutively activated Stat3. Transfection with dominant-negative Stat3, Stat3 siRNA, or Stat3 shRNA decreased IL-6 expression in AS2 cells. Conversely, transfection with constitutively-activated Stat3 increased the production of IL-6. In AS2 derived cells, resistance to paclitaxel was positively correlated with Stat3 activation status and the expression of IL-6, which is commonly secreted in drug resistant cancer cells. The pharmacological inhibition of NF-κB, PI3-K/Akt and MEK/Erk and the pharmacological inhibition and genetic inhibition (Stat3 siRNA) of Jak2/Stat3 pathway decreased IL-6 autocrine production in various drug resistant cancer cell lines and similarly decreased IL-6 autocrine production in clinically isolated lung cancer cells. Conclusions: This study is the first to directly address the role Stat3 plays on the autocrine production of IL-6, which occurs through a positive-feedback loop. Our biochemical and genetic studies clearly demonstrated that Jak2/Stat3, in combination with other IL-6 downstream pathways, contributed frequently and substantially to IL-6 autocrine production in a broad spectrum of cancer cell lines as well as in clinical cancer samples. Our findings suggest that Stat3 could potentially be regulated to suppress IL-6 autocrine production in cancer cells to inhibit the progression of cancer and reduce drug resistance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-9-309

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • STAT3 activation potentiates IL-6 signaling by increasing receptor and ligand levels.

    “STAT3 activation potentiates IL-6 signaling by increasing receptor and ligand levels”

    From Dynamic IL-6R/STAT3 signaling leads to heterogeneity of metabolic phenotype in pancreatic ductal adenocarcinoma cells (2024) · cites this paper as [38]

    The Discussion (page unavailable) reports that STAT3 contributes to IL-6 autocrine production in the cancer cells tested, supporting increased ligand production. The Background identifies the IL-6 receptor subunits gp80 and gp130, but the cited passages do not show that STAT3 increases receptor levels. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Huang, W.-L., Yeh, H.-H., Lin, C.-C., Lai, W.-W., Chang, J.-Y., Chang, W.-T., & Su, W.-C.
Affiliations
  • National Cheng Kung University (TW)
  • National Cheng Kung University Hospital (TW)
  • National Health Research Institutes (TW)
Corresponding author
Su, Wu-Chou
Venue
Molecular Cancer
Published
2010-12
Volume
9
Issue
1
Pages
309-309
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2170027004
Cited by
86
References
55
Citations by year
2026: 3 · 2025: 5 · 2024: 9 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 5 · 2014: 9 · 2013: 10 · 2012: 3
FWCI
3.17
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Council (DOH99-TD-C-111-003, NSC99-2120-M-006-005)
  • National Health Research Institutes
  • National Cheng Kung University
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
STAT3, JAK2/STAT3 signaling, interleukin-6, lung adenocarcinoma, paclitaxel resistance, MEK/ERK signaling, PI3K/Akt signaling, NF-κB, positive feedback loop, drug resistance, tumor progression
MeSH terms
Adenocarcinoma of Lung, Adenocarcinoma, Enzyme-Linked Immunosorbent Assay, Humans, Lung Neoplasms, Neoplasms, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Interleukin-6, Paclitaxel, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, RNA Interference, Cell Line, Tumor, STAT3 Transcription Factor, Janus Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review